Brought to you by 
Chelsea gains ww rights to Dainippon Sumitomo's droxidopa
29 Jun 2006
Executive Summary
Chelsea Therapeutics International (developing pharmaceuticals for unmet medical needs) has licensed exclusive worldwide rights (with the exception of Japan, Korea, China, and Taiwan) to Dainippon Sumitomo Pharma's Dops (droxidopa or DL-threo-3,4-dihydroxyphenylserine), a norepinephrine-induced adrenergic neurofunction improving agent.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chelsea gains ww rights to Dainippon Sumitomo's droxidopa
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice